Array BioPharma reports rise in Q2 revenue
The net loss was significantly reduced to $3.8m for the second quarter, compared to a net loss of $12.4m for the second quarter in fiscal 2011. The net
The US Food and Drug Administration (FDA) has approved PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) to treat adults with essential thrombocythaemia (ET).
Hydrochlorothiazide Capsules, 12.5mg, indicated for the management of hypertension, is therapeutically equivalent to the reference listed drug, Microzide Capsules, 12.5mg, of Watson Pharmaceuticals. The company is expected to